Auris Medical Holding Ltd. (EARS) News
Filter EARS News Items
EARS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EARS News Highlights
- 500 - Internal server error
- Over the past 18 days, the trend for EARS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about EARS are RNA, EAR and AIM.
Latest EARS News From Around the Web
Below are the latest news stories about Auris Medical Holding Ltd that investors may wish to consider to help them evaluate EARS as an investment opportunity.
Auris Medical launches new corporate websiteAuris Medical Holding (EARS) announces the launch of its newly-designed corporate website www.aurismedical.com. "...the new website reflects the company’s recent strategic move into RNA therapeutics, while highlighting the exciting prospects for its traditional businesses," CEO Thomas Meyer said.Shares down nearly 1% premarket.Auris had announced plans of its strategic repositioning, last month.... |
Auris Medical Announces Launch of New Corporate WebsiteHamilton, Bermuda, July 15, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the launch of its newly-designed corporate website www.aurismedical.com. The new website features a streamlined and modern design and also reflects the Company’s recently announced strategic repositioning. “We are proud to present our projects and products a |
Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2Bentrio™ formulation well tolerated in vitro on human nasal epitheliumUp to 99% reduction of SARS-CoV-2 viral titer with prophylactic treatment vs. controlsViral titer reduced 12- or 14-fold vs. controls when treatment started 24 or 30 h post infection Hamilton, Bermuda, July 14, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced addit |
Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ TechnologyTreatment of KRAS-driven colorectal cancer selected as first therapeutic indication for OligoPhore™ platformCompany to launch development program under project code AM-401 with aim of IND submission in late 2022 Hamilton, Bermuda, July 6, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the selection of mutant KRAS-driven colorectal |
Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in GermanyHamilton, Bermuda, June 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that its affiliate Altamira Medica Ltd. will start the market roll-out of Bentrio™, its nasal spray for protection against airborne viruses and allergens, by launching it in Germany. Bentrio™ will shortly become available through selected online pharmacies; |
Tinnitus Drug Pipeline Market 2021 by Product Type, Application, Region and Key Players - AudioCure Pharma GmbH , Auris Medical Holding AG, Autifony Therapeutics Ltd, Decibel Therapeutics LtdThe Tinnitus Drug Pipeline Market research report is prepared by an in-depth analysis of the present market status and historical data of the Medical Devices industry. The report offers valuable insights by studying the significant market segments such as top |
Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine Model of Adult T-Cell Leukemia / LymphomaTreatment with OligoPhoreTM siRNA stops aggressive ATLL tumor growth to near zeroSignificant reduction in tumor size, spleen size and peripheral blood lymphocyte countsResults add to extensive body of evidence for effective OligoPhoreTM enabled delivery of nucleic acids to extrahepatic tissues Hamilton, Bermuda, June 21, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inn |
Auris Medical Holding to Present at LD Micro Invitational XI ConferenceAuris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that Chairman and CEO Thomas Meyer will present at the LD Micro Invitational XI investor conference |
Auris Medical Announces Completion of Bentrio Conformity Assessment Procedure for Marketing in EUMeeting essential requirements for marketing BentrioTM in Europe under CE markOn track for first product launch in Europe towards end of Q2 2021 Hamilton, Bermuda, May 25, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, and its affiliate Altamira Medica Ltd. today announced that it has successfully completed the conformity assessment procedure for marketing the BentrioTM nasal spray in the member states of the European Union (EU). The product, which is intended to help protect against airborne allergens and viruses, is considered a Class I medical device under the Medical Devices Directive (MDD). BentrioTM therefore meets all... |
Auris Medical Provides Update on Bentrio Program in AllergyBentrioTM meets primary efficacy endpoint in clinical evaluation in allergic rhinitisClinically relevant and significant reduction in nasal symptomsSuperior efficacy ratings by patients and clinicians Pre-submission meeting with FDA supports 510(k) regulatory pathway Hamilton, Bermuda, May 7, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, and its affiliate Altamira Medica Ltd. today announced additional details on the outcomes from the clinical investigation of its BentrioTM nasal spray in allergic rhinitis and provided an update on the regulatory pathway in the US for the intended use in allergy. BentrioTM effectively allev... |